Emicizumab
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
Conditions
Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A
Trial Timeline
Feb 10, 2020 → Dec 19, 2025
NCT ID
NCT04158648About Emicizumab
Emicizumab is a phase 3 stage product being developed by Roche for Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor. The current trial status is completed. This product is registered under clinical trial identifier NCT04158648. Target conditions include Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Hemophilia A.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05181618 | Approved | Active |
| NCT04431726 | Phase 3 | Active |
| NCT04158648 | Phase 3 | Completed |
| NCT03315455 | Phase 3 | Completed |
| NCT03380780 | Phase 1 | Completed |
| NCT03191799 | Phase 3 | Completed |
Competing Products
20 competing products in Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor